Meiogenix, Announces the Constitution of a Scientific Advisory Board
Meiogenix, a genomic biotech company developing a technology that modulates meiotic recombination (SpiX®), has announced the constitution of its Scientific Advisory Board. Dr. Alain Nicolas will chair the SAB, and is joined by Prof. Holger Puchta and Prof. Philip Avner.
March 21, 2012
« During the past year, Meiogenix has made impressive advances with its R&D programs and I am confident that our scientific advisors will make significant contributions to our current and future R&D programs, thanks to the insights they bring, » says Dr. Alain Nicolas, inventor of the SpiX technology.
SpiX can redirect meiotic recombination towards targeted genome areas, and stimulate rare recombination events. This holds promise for the generation of novel, but still natural, genetic diversity, and addresses companies involved in varietal R&D. Meiogenix is currently evaluating the impact of its technologies in rice and mouse and developing complementary breakthrough technologies to modulate the meiotic recombination. Meiogenix seeks industrial collaborations to apply SpiX in other organisms of commercial relevance.